CORT News and Press, Corcept Therapeutics Incorporated From 01/07/24

2024-01-07 02:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-02 12:56:48 ET More on Mid-day movers & stocks. ENDRA Life Sciences Inc. (NDRA) Q3 2023 Earnings Call Transcript PolyPid Ltd. (PYPD) Q3 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Endra Life Sciences Historical earnings da...

2024-01-02 12:32:58 ET More on Corcept Therapeutics Analyzing Corcept's Strategic Shift In A Competitive Pharma Landscape Corcept Therapeutics Incorporated (CORT) Q3 2023 Earnings Call Transcript Biggest stock movers today: Apple, Unity Software, Li Auto, crypto-rela...

2024-01-02 10:00:09 ET More on Health Care Select Sector SPDR XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Covid-vaccine makers top laggard list, LLY and WST top gainers list Healthcare and uti...

MENLO PARK, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncology, metabolism, and neurology disorders by modulating the effects of the horm...

2024-01-02 06:48:18 ET Summary Number of electric vehicle models eligible for $7,500 tax credit in the US has fallen due to tighter rules on sourcing parts from Chinese suppliers. Bitcoin surpasses $45,000 for the first time in two years, driven by anticipation of US approval of a...

2024-01-01 21:34:53 ET Analyzing Corcept's Strategic Shift In A Competitive Pharma Landscape Corcept Therapeutics Incorporated (CORT) Q3 2023 Earnings Call Transcript Truist upgrades Corcept to buy, cites market potential for relacorilant Corcept Therapeutics Q3 ...

2023-11-30 03:45:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-11-13 13:58:11 ET Summary Corcept Therapeutics' strategic shift to relacorilant from Korlym addresses efficacy and safety, amidst Teva's patent dispute. Financially robust with 21.5% YOY revenue growth; however, increasing R&D costs and potential generic competition are c...

2023-11-06 16:06:39 ET More on Corcept Therapeutics Corcept Therapeutics Incorporated (CORT) Q3 2023 Earnings Call Transcript Corcept Therapeutics: Far More Constructive With Korlym Resolve (Rating Upgrade) Corcept Therapeutics Q3 2023 Earnings Preview Corcep...